Document Detail


Myocardial washout of 99mTc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis.
MedLine Citation:
PMID:  20454875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Early diagnosis and initiating treatment of cardiac sarcoidosis are essential because cardiac involvement is an important prognostic factor. Although there are many reports on the diagnosis of cardiac sarcoidosis, the literature on predicting the efficacy of steroid therapy is very limited. The purposes of this study were to investigate the myocardial washout of (99m)Tc-tetrofosmin (TF), and to evaluate the predictability of left ventricular (LV) functional recovery after steroid therapy in patients with cardiac sarcoidosis. METHODS: We performed TF-gated SPECT and echocardiography for ten patients with cardiac sarcoidosis before and after initiating steroid therapy. SPECT images were acquired at 30 min (early images) and 3 h (delayed images) after injection. We calculated the total defect score (TDS) and left ventricular ejection fraction (LVEF). The washout score (WOS) was considered as the difference between the early and delayed TDS. In addition, we defined DeltaLVEF as the change in LVEF after initiating steroid therapy. Furthermore, we analyzed the regional TF myocardial uptake (%uptake) and the regional LV function (wall thickness, WT) by the 20-segment model on polar maps as regional indices. The regional washout (RWO) was defined as the change in %uptake between the early and delayed images in TF SPECT before the therapy. We calculated the improvement factor of the regional LV function as DeltaWT (WT after initiating therapy - WT before the therapy) and investigated the relationships among the indices. RESULTS: We observed WO in 6 of 10 patients (60%). Decreased WT on echocardiography was observed in only 2 of 6 patients (33.3%) in the WO(+) group and in all 4 patients (100%) in the WO(-) group (p < 0.05). WOS before initiating steroid therapy exhibited a good correlation with DeltaLVEF (r = 0.685, p < 0.05). In the regional analysis, %uptake in the early images and delayed images before therapy did not significantly correlate with DeltaWT. In contrast, RWO before therapy was well correlated with DeltaWT (r = 0.435, p < 0.05). CONCLUSION: Our preliminary study shows that there is a relationship between washout of (99m)Tc-tetrofosmin and the LV functional recovery after steroid therapy in patients with cardiac sarcoidosis.
Authors:
Hirokazu Kudoh; Sei Fujiwara; Hideyuki Shiotani; Hiroya Kawai; Kenichi Hirata
Related Documents :
25311005 - Advances in retrograde technique for coronary chronic total occlusions.
15100505 - Intracoronary versus intravenous injection of 99mtc-tetrofosmin: comparison of myocardi...
8878125 - The use of gtn to improve the detection of ischaemic myocardium using 99tcm-tetrofosmin.
4000565 - Discriminant analysis of thallium-201 myocardial scintigrams.
15364855 - Pulmonary regurgitation is an important determinant of right ventricular contractile dy...
9627545 - Should patients be screened for asymptomatic carotid artery stenosis?
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2010-05-08
Journal Detail:
Title:  Annals of nuclear medicine     Volume:  24     ISSN:  1864-6433     ISO Abbreviation:  Ann Nucl Med     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-15     Completed Date:  2010-09-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8913398     Medline TA:  Ann Nucl Med     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  379-85     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiomyopathies / diagnosis,  drug therapy*,  metabolism*,  physiopathology
Echocardiography
Female
Heart / drug effects,  physiopathology
Humans
Male
Middle Aged
Myocardium / metabolism*
Organophosphorus Compounds / diagnostic use,  metabolism*
Organotechnetium Compounds / diagnostic use,  metabolism*
Recovery of Function
Sarcoidosis / diagnosis,  drug therapy*,  metabolism*,  physiopathology
Steroids / pharmacology,  therapeutic use*
Tomography, Emission-Computed, Single-Photon
Treatment Outcome
Ventricular Dysfunction, Left / physiopathology
Chemical
Reg. No./Substance:
0/Organophosphorus Compounds; 0/Organotechnetium Compounds; 0/Steroids; 0/technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Emergency Management of Acute Ischemic Stroke.
Next Document:  Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.